McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
Business Wire•01/10/2026•08:03 ET
1
Key Highlights
- ➤McKesson (MCK) extends CVS Health distribution partnership through June 2032
- ➤Agreement covers mail order, specialty, retail pharmacies, and distribution centers
- ➤McKesson (MCK) reaffirms fiscal 2027 adjusted EPS guidance of $44.20 to $45.00
- ➤McKesson (MCK) reaffirms long-term adjusted EPS growth rate of 13% to 16%
Expert Statements
Brian Tyler, Chair and chief executive officer of McKesson
“We are pleased to extend our long-standing, strategic relationship with CVS Health and continue supporting their important role in serving patients and communities across the country. For more than 25 years, our teams have worked together to deliver reliable, high-quality services to patients, and we remain committed to building on that strong foundation through our differentiated capabilities and shared focus on improving health outcomes.”
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032.
Get started
Create a free account to read the full story.